BACKGROUND: Vaginal HIV-1 shedding has been associated with Trichomonas vaginalis (TV) infection and could play a role in HIV transmission. The purpose of the study was to examine if effective TV treatment reduces the presence of vaginal HIV-1 RNA. METHODS: TV+ women attending an HIV outpatient clinic in New Orleans, LA, who resolved infection (n = 58) and TV-negative controls (n = 92), matched on antiretroviral therapy (ART) were examined and interviewed at baseline, 1, and 3 months. TV status was tested by culture and the amount of cell free HIV-1 RNA in the vaginal fluids was determined by the Amplicor HIV-1 Monitor ultrasensitive assay. RESULTS: : Most women (81.3%) were black and the mean age was 37.5 (SD 8.7). At baseline, 46.0% had plasma HIV-1 RNA >/=10,000 copies/mL, 26.4% had CD4<200 cells/muL, 54.7% were taking ART, and only 26.0% had detectable HIV-1 RNA in their vaginal fluids. TV-positive women who were effectively treated for TV were less likely to shed HIV vaginally at 3-months post-treatment compared to baseline (R.R. 0.34, 95% CI: 0.12-0.92, P = 0.03), whereas there was no change for TV-negative women. CONCLUSION: This study provides additional support that reducing TV infection among HIV-positive women may have an impact on the prevention of HIV transmission. Reasons for the delayed treatment effect and the effect on cervical shedding need further investigation.
BACKGROUND: Vaginal HIV-1 shedding has been associated with Trichomonas vaginalis (TV) infection and could play a role in HIV transmission. The purpose of the study was to examine if effective TV treatment reduces the presence of vaginal HIV-1 RNA. METHODS:TV+ women attending an HIV outpatient clinic in New Orleans, LA, who resolved infection (n = 58) and TV-negative controls (n = 92), matched on antiretroviral therapy (ART) were examined and interviewed at baseline, 1, and 3 months. TV status was tested by culture and the amount of cell free HIV-1 RNA in the vaginal fluids was determined by the Amplicor HIV-1 Monitor ultrasensitive assay. RESULTS: : Most women (81.3%) were black and the mean age was 37.5 (SD 8.7). At baseline, 46.0% had plasma HIV-1 RNA >/=10,000 copies/mL, 26.4% had CD4<200 cells/muL, 54.7% were taking ART, and only 26.0% had detectable HIV-1 RNA in their vaginal fluids. TV-positive women who were effectively treated for TV were less likely to shed HIV vaginally at 3-months post-treatment compared to baseline (R.R. 0.34, 95% CI: 0.12-0.92, P = 0.03), whereas there was no change for TV-negative women. CONCLUSION: This study provides additional support that reducing TV infection among HIV-positive women may have an impact on the prevention of HIV transmission. Reasons for the delayed treatment effect and the effect on cervical shedding need further investigation.
Authors: Barbara Van Der Pol; James A Williams; Donald P Orr; Byron E Batteiger; J Dennis Fortenberry Journal: J Infect Dis Date: 2005-11-08 Impact factor: 5.226
Authors: R Scott McClelland; Laura Sangare; Wisal M Hassan; Ludo Lavreys; Kishorchandra Mandaliya; James Kiarie; Jeckoniah Ndinya-Achola; Walter Jaoko; Jared M Baeten Journal: J Infect Dis Date: 2007-01-22 Impact factor: 5.226
Authors: C E Hart; J L Lennox; M Pratt-Palmore; T C Wright; R F Schinazi; T Evans-Strickfaden; T J Bush; C Schnell; L J Conley; K A Clancy; T V Ellerbrock Journal: J Infect Dis Date: 1999-04 Impact factor: 5.226
Authors: B K Patterson; A Landay; J Andersson; C Brown; H Behbahani; D Jiyamapa; Z Burki; D Stanislawski; M A Czerniewski; P Garcia Journal: Am J Pathol Date: 1998-08 Impact factor: 4.307
Authors: S B Mostad; S Jackson; J Overbaugh; M Reilly; B Chohan; K Mandaliya; P Nyange; J Ndinya-Achola; J J Bwayo; J K Kreiss Journal: J Infect Dis Date: 1998-10 Impact factor: 5.226
Authors: A K Iversen; L Fugger; J Eugen-Olsen; U Balslev; T Jensen; S Wahl; J Gerstoft; J I Mullins; P Skinhoj Journal: J Infect Dis Date: 1998-11 Impact factor: 5.226
Authors: Megan Gatski; David H Martin; Judy Levison; Leandro Mena; Rebecca A Clark; Mary Murphy; Harold Henderson; Norine Schmidt; Patricia Kissinger Journal: Sex Transm Infect Date: 2011-01-29 Impact factor: 3.519
Authors: Megan Gatski; Leandro Mena; Judy Levison; Rebecca A Clark; Harold Henderson; Norine Schmidt; Susan L Rosenthal; David H Martin; Patricia Kissinger Journal: Sex Transm Dis Date: 2010-08 Impact factor: 2.830
Authors: Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: Benson Singa; Sara Nelson Glick; Naomi Bock; Judd Walson; Linda Chaba; James Odek; R Scott McClelland; Gaston Djomand; Hongjiang Gao; Grace John-Stewart Journal: Sex Transm Dis Date: 2013-02 Impact factor: 2.830
Authors: Charlotte A Gaydos; Marcia Hobbs; Jeanne Marrazzo; Jane Schwebke; Jenell S Coleman; Billie Masek; Laura Dize; Dan Jang; Jenny Li; Max Chernesky Journal: Sex Transm Dis Date: 2016-06 Impact factor: 2.830
Authors: Christine Mauck; Pai-Lien Chen; Charles S Morrison; Raina N Fichorova; Cynthia Kwok; Tsungai Chipato; Robert A Salata; Gustavo F Doncel Journal: AIDS Res Hum Retroviruses Date: 2016-01-26 Impact factor: 2.205